Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu
© Borgis - Postępy Nauk Medycznych 5/2010, s. 431-433

Dear Colleagues!
Department of Family Medicine and Internal Diseases is one of the clinics at the Medical Center of Postgraduate Education (CMKP) which is providing education courses in internal medicine for specializing doctors whose goal is to practice family medicine. Four years ago, specialists working in this Department began to organize continuous education programs in the field of internal diseases for family physicians and other physicians who work in primary outpatient clinics.
Together with the continuous education programs, we prepare special issues of "Progress in Medicine” (a journal under the patronage of CMKP). Those issues are distributed among the participants of our courses as training materials and are also delivered to doctors of other specializations who are interested in internal medicine. The special issues have been very well received by family physicians and other readers of "Progress in Medicine”. They have become an important element of the training process of doctors in a variety of specializations. In the current volume of the journal, we have focused on internal diseases of pregnant women. The issues relating to pregnancy are an interdisciplinary problem that concerns not only gynecologists, midwives, internists, diet doctors, pediatricians, but also family doctors. While preparing this volume, we bore in mind that among primary health care doctors are professionals of different specializations and of varied expertise.
In the current issue, there are 12 articles focusing on different aspects of internal medicine and pregnancy. The article entitled "The influence of Vitamin D deficiency during pregnancy and lactation on the mother and the child” by E. Marcinowska-Suchowierska and Magdalena Walicka reports that women with serious Vitamin D deficiency during pregnancy have an increased risk for preeclampsia, and their children – right after birth – for seizures with hypocalcemia. The effect of Vitamin D deficiency during pregnancy is birth of a baby with Vitamin D deficiency which can result in the development of rickets, defects of tooth bone, decreased bone mass, increased risk for fractures, increased development of various diseases. Nowadays, it is known that pregnant women require Vitamin D supplementation from the second trimester of pregnancy. It is recommended that adults require a minimum of 800-1000 j.m./day when the exposition to the sun is inadequate (in Poland from October to April). This dosage should be given to all women who avoid being exposed to sunlight. From April to September, taking into consideration sun exposure to 18% of the skin for 15 minutes per day, additional supplementation of Vitamin D should be 400 IU per day.
The article entitled "Prophylaxis of Vitamin D Deficiency – Polish Recommendation 2009”, presents, based on current literature review and opinions of National Consultants and experts in the field, Polish recommendations for prophylactic vitamin D supplementation in infants, toddlers, children and adolescents as well as in adults, including pregnant and lactating women.
The article entitled "Diabetes and pregnancy” by M. Walicka, E. Czerwińska and E. Marcinowska - Suchowierska reports that diabetes mellitus can occur during pregnancy in 2 forms: pregestational and gestational diabetes. Both types of diabetes need special care during pregnancy. Pregestational diabetes represents very high-risk obstetrics. Gestational diabetes confers a much lower risk for both the mother and the fetus but is growing in prevalence. Recent studies show that diagnosis and management of this disorder have beneficial effects on maternal and neonatal outcomes. Diagnosis is made using a sequential model of universal screening with a 50-g one-hour glucose challenge test, followed by a diagnostic 75-g oral glucose tolerance test for women with a positive screening test. Treatment consists of glucose monitoring, dietary modification, exercise, and, when necessary, pharmacotherapy to maintain euglycemia. Insulin therapy is the mainstay of treatment, although glyburide and metformin may become more widely used. Women with gestational diabetes are at high risk of subsequent development of type 2 diabetes. Lifestyle modification should therefore be encouraged, along with regular screening for diabetes.
The article entitled "Hypertension in pregnant women” by M. Wąsowski and E. Marcinowska-Suchowierska reports that hypertension in pregnancy is, despite of progress in medical science, an important cause of maternal, fetal and neonatal morbidity and mortality. It occurs in approximately 3-15% of pregnancies and in 70% of women with first gestation. This article provides guidelines for diagnosis and treatment of high blood pressure in pregnancy based on ESH, PSH and ESC guidelines and current references.
The article entitled "Pulmonary emboliom” by A. Bogołowska-Stieblich and E. Marcinowska-Suchowierska reports that pulmonary embolism is the most common cause of death among pregnant women in well developed countries. Changes of hormones concentration, physiological changes in coagulation system and compression of large vessels by the enlarged uterine take place in pregnancy what leads to higher risk of thromboembolism development. Symptoms suggesting deep vein thrombosis (DVT) or pulmonary embolism (PE) can occur during pregnancy without thromboembolism. Furthermore, pulmonary embolism diagnostics has many limitations caused by unspecific VT symptoms, physiological elevated D-dimers concentration or potentially fatal influence of ionizing radiation on fetus. VT treatment in pregnant women can cause complications in both the mother and the fetus. A very careful medicine selection is most important to reduce potential complications. Prophylaxis is very significant among women with higher risk of thromboembolism development. Mechanical methods should be considered in every group of patients and in some of them pharmacological methods as well. In groups with higher risk of thromboembolism pharmacological prophylaxis during postpartum period should be applied. Anticoagulation treatment should be stopped before delivery and ought to be continued just after it. We have to remember that anticoagulation can be exert during breast-feeding including vitamin K antagonists.
The article entitled "Rheumatic diseases in pregnant women” by A. Jasik and E. Marcinowska-Suchowierska reports that rheumatic diseases often occur in young people, including women in the reproductive age. The main rheumatic diseases which we can find in pregnant women are: rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The safety of pharmacotherapy in these diseases during pregnancy and lactation is very important. The most commonly used nonsteoridal anti inflammatory drugs should be used in the lowest therapeutically sufficient dose. Among the glicocorticoids, prednisone and prednisolon have the safest profile in pregnancy. Methotrexate, Cyclophosphamide and Leflunomide are contraindicated in pregnancy. The reports on the safety of the biological treatment during pregnancy are optimistic, however still not sufficient. Pregnancy in women with SLE can be complicated by preeclampsia, premature labour or miscarriage more often than in the healthy population, and it is considered a high- risk pregnancy. Symptoms of preeclampsia and SLE exacerbation are similar, so they need to be correctly differentiated. APS is associated with several pregnancy complications too. Treatment in this disease is still equivocal. Therapeutic schemes involve aspirin and heparins – preferable low molecular weight heparins. Steroids and immunoglobulins are not routinely used. Treatment in APS administrated in early pregnancy increases chances for life delivery to 80%.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
Postępy Nauk Medycznych 5/2010
Strona internetowa czasopisma Postępy Nauk Medycznych